# Evoke Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evoke-pharma

- Industry: Pharmaceuticals
- Headquarters: Solana Beach, US
- Website: www.evokepharma.com
- Total disclosed funding: $3M
- Latest round: Series A (Jun 7, 2007)
- Investors on record: 2

## About

Evoke Pharma, Inc. is a US-based biopharmaceutical company dedicated to developing innovative treatments for gastrointestinal diseases, particularly diabetic gastroparesis, aimed at improving patient care and therapeutic outcomes.Founded in 2007 and headquartered in Solana Beach, US, Evoke Pharma, Inc. focuses on the development of therapies for diabetic gastroparesis. The company was established by Dave Gonyer and Matt D'Onofrio, who have a history of expertise in the pharmaceutical sector. Evoke Pharma successfully raised USD 25 million from its IPO in September 2013 and generated a total of USD 12.50 million in a Private Placement/Follow on in January 2021, which represents the total amount raised.Evoke Pharma, Inc. specializes in creating treatments for gastrointestinal diseases, focusing on diabetic gastroparesis. Their flagship product addresses symptoms caused by slow gastric emptying, enhancing gastric motility to improve treatment effectiveness. This medication, released over a decade ago, significantly aids patients struggling with inadequate relief from orally administered therapies. The company primarily serves patients and healthcare professionals throughout the United States, ensuring access to medications and support resources.In the most recent fiscal year of 2023, Evoke Pharma reported a revenue of USD 5.18 mn. During the same period, they encountered an EBITDA loss of USD 7.43 mn, reflecting the financial dynamics associated with their specialized product offerings and market presence.Evoke Pharma plans to enhance its product portfolio with new treatments aimed at expanding its market reach. The company is exploring opportunities to introduce additional gastrointestinal therapies within the next few years. Furthermore, Evoke Pharma is targeting expansion into new geographic markets to broaden patient access to its products. The funds raised in the Private Placement/Follow on in January 2021 will be allocated to these strategic initiatives, supporting the development and commercialization of their new offerings. The overall strategy aims to strengthen their position in the healthcare market by addressing unmet needs in patient care.

## Funding rounds

- Series A, Jun 7, 2007, $3M — Domain Associates, Latterell Venture Partners

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series A